New Research Raises Concerns About Safety of Higher-THC Medicinal Cannabis Products in Australia

New research raises concerns about safety of higher-THC medicinal cannabis products in Australia

New Monash University research has found that more than half of all adverse events reported to Australia's medicines regulator involving medicinal cannabis were linked to higher-THC products, with psychiatric disorders the most commonly reported adverse reactions.

Medicinal cannabis adverse event study provides useful early warnings, but with limitations

Mills Oakley partners Dr Teresa Nicoletti and Geoff Bloom unpack the TGA’s recent analysis of adverse […] The post Medicinal cannabis adverse event study provides useful early warnings, but with limitations appeared first on Cannabiz.